NICE OK for life-extending Vizimpro in lung cancer
It’s a change from the committee’s initial decision which found the tyrosine kinase inhibitor to not be a cost-effective use of NHS resources.
Read More
Tag: dacomitinib
US green light for Pfizer’s lung cancer drug
Pfizer’s pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib has been approved in the US as a treatment for some forms of lung cancer.
Read More
Pfizer files lung cancer drug in the EU, US
Pfizer has filed its pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib on both sides of the Atlantic for a particular form of lung cancer.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
